InformationCCG-222740 CCG-222740 is a Rho/MRTF pathway inhibitor. CCG-222740 decreases the activation of stellate cells in vitro and in vivo, by reducing the levels of alpha smooth muscle actin(α-SMA) expression.TargetsRho ; α-SMAIn vitroCCG-222740 increases the protein levels of p27 and decreased cyclin D1. CCG-222740 treatment decreased cell viability of CAFs, with an IC50 of~10 μM, as measured by the MTT assay. In pancreatic cancer, CAFs are one of the main producers of matrix proteins, including several collagen isoforms. The Rho/MRTF pathway inhibitor CCG-222740 decreases the levels of collagens I, 2a and IV, as well as α-SMA in the CAFsIn cancer cells. CCG-222740 treatment leads to the exclusion of MRTF from the nucleus. .In vivoCCG-222740 significantly reduces α-SMA levels in the pancreas of caerulein- stimulated KC mice.Cell Research(from reference)Cell lines：Cancer associated fibroblasts (CAFs) Concentrations：10 μM and 20 μM Incubation Time：72 hours. Specification: 0.98 Molecular Formula: C23H19ClF2N2O3 Molecular Weight: 444.86 PubChem CID: 121317937 Isomeric SMILES: C1C(CN(CC1(F)F)C(=O)C2=CC=CC(=C2)C3=CC=CO3)C(=O)NC4=CC=C(C=C4)Cl
- UPC:
- 51172451
- Condition:
- New
- Availability:
- 2 weeks
- Weight:
- 0.97 Ounces
- HazmatClass:
- No
- WeightUOM:
- LB
- MPN:
- C413579-100mg
- CAS:
- 1922098-69-8
- Product Size:
- 100mg
